Patents Examined by Patricia Duffy
  • Patent number: 10548904
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 4, 2020
    Assignee: FERRING B.V.
    Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
  • Patent number: 10550437
    Abstract: A culture medium for culturing Clostridium difficile under aerobic culture conditions, the medium includes a nutrient medium that promotes growth of Clostridium difficile and amounts of thioglycolic and L-cystine effective to consume oxygen in the culture medium and facilitate growth of Clostridium difficile.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: February 4, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Curtis Donskey, Michelle Nerandzic, Jennifer Cadnum
  • Patent number: 10544194
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 28, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • Patent number: 10537584
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: January 21, 2020
    Assignee: FERRING B.V.
    Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
  • Patent number: 10532134
    Abstract: In described embodiments, the present invention includes a magnesium-based composite material formed from a plurality of ?-phase magnesium grains; and a ?-alloy phase comprising magnesium and nano-diamond and/or and phosphate containing nanoparticles, the ?-alloy phase surrounding each of the plurality of magnesium grains. A method of manufacturing a composite material is also disclosed.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 14, 2020
    Assignee: Drexel University
    Inventors: Gongyao Zhou, Haibo Gong, Donggang Yao
  • Patent number: 10509035
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 17, 2019
    Assignee: GAMAMABS PHARMA SA
    Inventors: Olivier Dubreuil, Jean-Marc Barret, Jean-François Prost, Delphine Desigaud
  • Patent number: 10494416
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 3, 2019
    Assignees: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Patent number: 10472398
    Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: November 12, 2019
    Assignees: Massachusetts Institute of Technology, The Governors of The University of Alberta
    Inventors: Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Gane Ka-Shu Wong, Yongku Peter Cho
  • Patent number: 10472399
    Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 12, 2019
    Assignees: Massachusetts Institute of Technology, The Governors of The University of Alberta
    Inventors: Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Gane Ka-Shu Wong, Yongku Peter Cho
  • Patent number: 10463748
    Abstract: The present invention provides antibodies that bind to Staphylococcus aureus Hemolysin A toxin, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Hemolysin A. The antibodies of the invention are useful for inhibiting or neutralizing Hemolysin A activity, thus providing a means of preventing or treating a Hemolysin A-related disease or disorder such as S. aureus infection. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of a S. aureus infection.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: November 5, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Alida Coppi, Peter Mason, William Olson
  • Patent number: 10456339
    Abstract: The aspects presented herein provide methods and compositions for the reduction of the peroxide value of perfume ingredients, formulated perfumes, formulated body care products, formulated skin care products, formulated homecare products, essential oils, food raw materials, formulated food products, and natural extracts.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 29, 2019
    Assignee: FIRMENICH SA
    Inventors: Michael J. Calandra, Ying Wang
  • Patent number: 10441516
    Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 15, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Venda Porter, Andre Morgan, Michael Prencipe, Sarita Mello
  • Patent number: 10435417
    Abstract: A process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration is described. The process is carried out using specifically controlled crystallization conditions.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 8, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 10413504
    Abstract: Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wouter de Graaff, Willy J. H. Verhoeven
  • Patent number: 10407743
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumors and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 10, 2019
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Patent number: 10400114
    Abstract: A composition comprising an ethylene (meth)acrylic acid copolymer and an anti-fouling agent is provided. The composition selectively disintegrates in media of different ionic strengths. Also provided is a method of preventing fouling using the composition.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: September 3, 2019
    Assignee: Rohm and Haas Company
    Inventors: Scott Backer, Afia S. Karikari, Paul Mercando
  • Patent number: 10383818
    Abstract: The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 20, 2019
    Assignee: VITUX GROUP AS
    Inventors: Ingvild Haug, Kurt Ingar Draget
  • Patent number: 10364298
    Abstract: A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16:1, C 18:0 or C18:1 fatty acid or any combination thereof wherein one of COR3 or COR4 may be replaced by H. Further described are conjugates comprising the novel LTA and vaccines produced using the isolated LTA and the LTA conjugates. The invention also encompasses methods of conferring immunity against C. difficile comprising administering a vaccine of the invention, and methods of detecting C. difficile using the isolated LTA of the invention.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 30, 2019
    Assignee: National Research Council of Canada
    Inventors: Christopher Reid, Susan M. Logan, Evguenii Vinogradov, Andrew Cox, Jean-Robert Brisson
  • Patent number: 10323232
    Abstract: This disclosure relates to the engineering of phototrophic microorganisms for conversion of alkanes into higher-value products. Recombinant phototrophic organisms such as cyanobacteria can be engineered, optionally in a modular format, to express enzymes involved in converting methane to methanol, methanol to formaldehyde, formaldehyde to central metabolic pathway intermediates, and such intermediates to n-butanol.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: June 18, 2019
    Assignee: MOgene LC
    Inventors: Abhay Singh, Himadri Pakrasi, Ganesh M. Kishore
  • Patent number: 10314903
    Abstract: Here we show that SEG/SEI presented from a HLA-DQ8 (HLA-DQB*0302 and HLA-DQA*0301) platform prevent the de novo outgrowth (vaccination) of Lewis lung carcinoma (LLC) and B16-F10 melanoma and retard the growth of established tumors with no significant toxicity. Vaccination of DQ8 tg mice with irradiated LLC or B16-F10 melanoma followed by SEG/SEI immunization and live tumor challenge resulted in 100 and 66% survival respectively for 200 days compared to a median survival of 20 days for untreated controls (p<0.001). In vaccination studies, DQ8 tg mice showed a surge in IFN? serum levels reaching 3000 fold above baseline devoid of a parallel spike in TNF? levels above baseline levels. Presentation of the SEG/SEI superantigen from a MHC-DQ8 platform, therefore, augments the therapeutic index of these SAgs inducing a tumoricidal response against Lewis lung carcinoma and B16 melanoma accompanied by a sharp increase of therapeutic IFN? levels absent toxic levels of TNF?.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: June 11, 2019
    Inventors: David S Terman, David Bradley